Retirement Systems of Alabama grew its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) by 0.2% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 184,728 shares of the biopharmaceutical company’s stock after acquiring an additional 372 shares during the quarter. Retirement Systems of Alabama’s holdings in Halozyme Therapeutics were worth $7,367,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. Spire Wealth Management lifted its holdings in shares of Halozyme Therapeutics by 3,200.0% during the fourth quarter. Spire Wealth Management now owns 2,013 shares of the biopharmaceutical company’s stock worth $81,000 after purchasing an additional 1,952 shares during the period. Covestor Ltd acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter worth $114,000. Captrust Financial Advisors lifted its holdings in shares of Halozyme Therapeutics by 12.1% during the third quarter. Captrust Financial Advisors now owns 2,898 shares of the biopharmaceutical company’s stock worth $118,000 after purchasing an additional 313 shares during the period. Acadian Asset Management LLC acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter worth $122,000. Finally, Lazard Asset Management LLC lifted its holdings in shares of Halozyme Therapeutics by 25.2% during the fourth quarter. Lazard Asset Management LLC now owns 3,177 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 639 shares during the period. 92.53% of the stock is owned by institutional investors and hedge funds.
Several research analysts have issued reports on the company. StockNews.com cut Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 11th. SVB Leerink assumed coverage on Halozyme Therapeutics in a research report on Monday, May 23rd. They issued an “outperform” rating and a $52.00 price objective for the company. Finally, The Goldman Sachs Group increased their price objective on Halozyme Therapeutics from $48.00 to $60.00 and gave the stock a “buy” rating in a research report on Thursday, May 26th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $52.33.
Shares of HALO stock opened at $46.33 on Wednesday. Halozyme Therapeutics, Inc. has a fifty-two week low of $31.36 and a fifty-two week high of $48.58. The stock has a market cap of $6.39 billion, a P/E ratio of 15.50, a P/E/G ratio of 0.70 and a beta of 1.20. The business has a fifty day simple moving average of $43.72 and a 200-day simple moving average of $39.56. The company has a quick ratio of 8.42, a current ratio of 8.85 and a debt-to-equity ratio of 3.03.
Halozyme Therapeutics (NASDAQ:HALO – Get Rating) last announced its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported $0.43 earnings per share for the quarter, missing analysts’ consensus estimates of $0.45 by ($0.02). Halozyme Therapeutics had a net margin of 92.23% and a return on equity of 132.71%. The firm had revenue of $117.30 million during the quarter, compared to analysts’ expectations of $128.25 million. During the same quarter in the prior year, the business earned $0.34 EPS. The company’s quarterly revenue was up 31.8% compared to the same quarter last year. On average, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 2.06 earnings per share for the current year.
Halozyme Therapeutics Company Profile (Get Rating)
Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company’s products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
See Also
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating).
Receive News & Ratings for Halozyme Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Halozyme Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
